A Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.

NCT07590661 · tracked via the Priya Life Science China tracker

Sponsor

Hangzhou Dinova EP Technology Co., Ltd

Phase

Not applicable

Started

2026-04-30

Last updated

2026-05-15

Condition(s) studied

Persistent Atrial Fibrillation

Investigational drug(s) / intervention(s)

superior vena cava isolationAbnormal left atrial substrate

superior vena cava isolation: Left atrial substrate mapping is performed after pulmonary vein ablation. For patients with abnormal left atrial substrate, superior vena cava isolation isolation will be conducted in the experimental group.

Abnormal left atrial substrate: Left atrial substrate mapping is performed following pulmonary vein ablation. For patients with abnormal left atrial substrate, superior vena cava isolation will be carried out in the control group.

Study summary

This prospective, multicenter, randomized controlled study was designed to investigate the feasibility, efficacy and safety of pulsed field ablation (PFA) strategies for persistent atrial fibrillation. For patients with persistent atrial fibrillation and normal left atrial substrate, pulmonary vein isolation combined with superior vena cava isolation will be performed. For those with abnormal left atrial substrate, two strategies will be adopted: pulmonary vein isolation plus superior vena cava isolation, and pulmonary vein isolation combined with superior vena cava isolation and left atrial posterior wall isolation. Long-term follow-up will be conducted to observe the long-term clinical outcomes.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: 1. Older than 18 years. 2. Diagnosed as persistent atrial fibrillation (AF); Definition: At least one episode of persistent AF was recorded on dynamic electrocardiogram (ECG) data within 12 months prior to enrollment, or other clinical evidence supporting persistent AF episodes lasting more than 7 days. 3. Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program. Exclusion Criteria: 1. Atrial fibrillation is secondary to thyroid disease or other reversible factors. 2. Evidence of left atrial or left atrial appendage thrombus on imaging examination. 3. Rheumatic heart disease or the presence of moderate to severe mitral stenosis or regurgitation. 4. Left ventricular ejection fraction \<40% or New York Heart Association (NYHA) class III/IV. 5. Left atrial anteroposterior diameter \>55 mm. 6. Unstable angina. 7. Myocardial infarction (MI), coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI) within 3 months prior to enrollment. 8. Previous catheter ablation or surgical ablation for atrial fibrillation. 9. History of prior left atrial appendage closure, patent foramen ovale closure, atrial septal defect closure, or repair surgery. 10. Implantation of a mechanical mitral valve prosthesis or metallic annuloplasty rings. 11. Presence of intracardiac thrombus, space-occupying lesions, or other abnormalities that preclude vascular access or catheter manipulation. 12. Contraindications to anticoagulation or history of coagulation disorders/abnormal bleeding. 13. Active systemic infection. 14. Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² or history of renal dialysis. 15. Severe hepatic dysfunction. 16. Pregnancy or breastfeeding. 17. Life expectancy \<12 months (e.g., advanced malignancy). 18. Current or anticipated participation in other drug or device clinical trials. 19. Any other condition or abnormality deemed by the investigator to warrant exclusion.

Primary outcome measure(s)

12-month atrial fibrillation (AF) ablation success rate — 12 months post-procedure
Defined as the absence of AF, atrial flutter (AFL), or atrial tachycardia (AT) episodes ≥30 seconds on dynamic electrocardiogram (ECG) monitoring after the blanking period (90 days post-catheter ablation)

Trial sites (1)

Facility	City	Region	Status
Fuwai Yunnan Hospital	Kunming	Yunnan

More Hangzhou Dinova EP Technology Co., Ltd trials in China

Comparison of Different Pulsed Field Ablation Catheters in Atrial Fibrillation Recruiting

Study on the Safety and Effectiveness of the SnowyTM PFO Closure System Starting soon

An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia Recruiting

Other trials for the same condition

Renal Denervation Combined With Pulsed Field Ablation to Prevent Recurrence in Persistent Atrial Fibrillation Active, not recruiting

Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation Recruiting

Pulsed Field Ablation Versus Radiofrequency Ablation: Effects of Pulmonary Vein Isolation Combined With Left Atrial Posterior Wall Isolation on Postoperative Gastric Motility in Patients With Persistent Atrial Fibrillation Starting soon

FIH Study of PFLotus in Persistent Atrial Fibrillation Recruiting

PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07590661 on ClinicalTrials.gov ↗ ← All trials in China